预防性尼莫地平用于前庭神经鞘瘤术后听力保护:随机多中心III期试验方案(AkniPro 2)
主要终点为出院前根据GR 1-3 vs GR 4-5二分类的耳蜗神经功能。
要点
- 预防性尼莫地平可能改善前庭神经鞘瘤术后听力保留。
- 主要终点为出院前GR 1-3 vs GR 4-5二分类的耳蜗神经功能。
- 尼莫地平除剂量依赖性低血压外为已知安全药物。
核心结论
- 预防性静脉尼莫地平可能对前庭神经鞘瘤手术听力保留有积极作用并改善患者生活质量。
- 未来预防性尼莫地平可能被推荐为前庭神经鞘瘤手术常规用药。
研究设计与样本
- 随机、多中心、两臂、开放标签III期试验,采用盲法专家评审和两阶段期中分析。
主要发现
- 此前112例III期试验中尼莫地平组术后听力丧失风险较对照组减半(OR 0.49;95% CI 0.18-1.30;p = 0.15)。
- 此前试验主要终点为面神经功能保护,未显示明确的面神经和耳蜗神经功能保护获益。
关键数值与推荐
- 干预组:术前一天至术后第五天静脉尼莫地平1-2 mg/h联合标准治疗;对照组:手术联合标准治疗。
- 主要终点:出院前根据GR 1-3 vs GR 4-5二分类评估的耳蜗神经功能。
- 听力功能通过术前和术后 audiometry 伴言语识别率测定,由盲法专家评审。
临床怎么用
- 预防性尼莫地平可能作为前庭神经鞘瘤手术常规用药用于听力保护。
- 尼莫地平除剂量依赖性低血压外为已知安全药物。
- 前庭神经鞘瘤可作为神经保护临床评价的理想模型,因听力结局可按公认标准分类。
局限性
- 试验为开放标签设计,但采用盲法专家评审。
- 尼莫地平存在剂量依赖性低血压风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A previously performed phase III trial on 112 subjects investigating prophylactic nimodipine treatment in vestibular schwannoma (VS) surgery showed no clear beneficial effects on preservation of facial and cochlear nerve functions, though it should be considered that protection of facial nerve function was the primary outcome. However, the risk for postoperative hearing loss was halved in the nimodipine group compared to the control group (OR 0.49; 95% CI 0.18-1.30; p = 0.15). Accordingly, this phase III extension trial investigates the efficacy and safety of prophylactic nimodipine for hearing preservation in VS surgery. METHODS: This is a randomized, multi-center, two-armed, open-label phase III trial with blinded expert review and two-stage with interim analysis. Three hundred thirty-six adults with the indication for microsurgical removal of VS (Koos I-IV) and serviceable preoperative hearing (Gardner-Robertson scale (GR) 1-3) are assigned to either the therapy (intravenous nimodipine 1-2 mg/h from the day before surgery until the fifth postoperative day and standard of care) or the control group (surgery only and standard of care). The primary endpoint of the trial is postoperative cochlear nerve function measured before discharge according to GR 1-3 versus GR 4-5 (binary). Hearing function will be determined by pre- and postoperative audiometry with speech discrimination, which will be evaluated by a blinded expert reviewer. Furthermore, patient-reported outcomes using standardized questionnaires will be analyzed. DISCUSSION: Prophylactic parenteral nimodipine treatment may have a positive effect on hearing preservation in VS surgery and would improve patient's quality of life. Further secondary analyses are planned. Except for dose-depending hypotension, nimodipine is known as a safe drug. In the future, prophylactic nimodipine treatment may be recommended as a routine medication in VS surgery. VS can be considered as an ideal model for clinical evaluation of neuroprotection, since hearing outcome can be classified by well-recognized criteria. The beneficial effect of nimodipine may be transferable to other surgical procedures with nerves at risk and may have impact on basic research. TRIAL REGISTRATION: EudraCT 2019-002317-19, DRKS00019107 . 8th May 2020.
引用
- Scheller C, Strauss C, Leisz S, et al. Prophylactic nimodipine treatment for hearing preservation after vestibular schwannoma surgery: study protocol of a randomized multi-center phase III trial-AkniPro 2. Trials. 2021. PMID: 34294114. doi:10.1186/s13063-021-05417-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。